Bearish flow noted in GSK (GSK) Pharma with 5,611 puts trading, or 3x expected. Most active are Mar-25 36.5 puts and 3/14 weekly 39.5 calls, with total volume in those strikes near 6,100 contracts.

Chloe Thornton commented: "The strength of GSK's oncology portfolio against a backdrop of decline elsewhere across its pharma business somewhat calls into question the decision to trade these ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to ...

A more precise and comprehensive answer to the above question allows me to firstly determine what difficulties arose in running GSK's business and, secondly, how effectively its management is able ...

answer questions and share ideas. Another part of the strategy has been to prioritise a few channels of communications that GSK identified as being the most effective. While the strategy allows ...

Shareholders and analysts question GSK’s plan to deliver £40bn in annual revenue by 2031, which is based on replacing income from its majority-owned blockbuster HIV drug dolutegravir towards ...

("GSK" or the "Company") (NYSE ... If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these ...

In trading on Tuesday, shares of GSK plc (Symbol: GSK) crossed above their 200 day moving average of $38.45, changing hands as high as $39.19 per share. GSK plc shares are currently trading up ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK ... have a significant presence in the US. However, questions of whether they will hire more people in the US compared ...